



# SVB LEERINK ANNUAL GLOBAL HEALTHCARE CONFERENCE

February 16, 2022

# FORWARD-LOOKING STATEMENTS

---

This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding possible or assumed future results of operations, business strategies, research and development plans, regulatory activities, market opportunity, competitive position and potential growth opportunities are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our reliance on the maintenance on certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of the COVID-19 pandemic on our business and operations; the performance of third parties in connection with the development of our product candidates, including third parties conducting our future clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and available at [www.sec.gov](http://www.sec.gov). You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

# CENTURY THERAPEUTICS - EMERGING LEADER IN ALLOGENEIC CELL THERAPIES FOR CANCER

## NEXT GENERATION iPSC-DERIVED PLATFORMS

iNK and iT platforms

## LEADING iPSC CELL ENGINEERING CAPABILITIES

Proprietary CRISPR MAD7 gene editing, binders and CARs

## FOUNDATION IN SCIENCE

Continuing investment in innovation drives R&D

## EXPECTING TO ENTER CLINIC IN 2022

CNTY-101 Phase 1 ELiPSE-1 expected to initiate 2H22

## FINANCIAL STRENGTH

Greater than \$500M proforma cash, cash equivalents and marketable securities<sup>1</sup>

## EMERGING PIPELINE OF CANDIDATES

Product engine anticipated to deliver 5 INDs over the next 3 years


## BMS DISCOVERY COLLABORATION

Initial focus on AML (CNTY-104) and Multiple Myeloma (CNTY-106)



<sup>1</sup> Total cash, cash equivalents and marketable securities of \$400.3M as of 9/30/2021 plus upfront payment (\$100M) and equity investment (\$50M) received from BMS for discovery collaboration announced 1/10/2022

# CENTURY'S EMERGING FRANCHISES



## B cell malignancies

- **CNTY-101:** Lead product candidate, CD19 targeted CAR-iNK
- **CNTY-102:** First  $\gamma\delta$  iT candidate, multi-specific (CD19 + CD79b) CAR-iT

Next generation cell therapy – will be first product to enter the clinic with edits designed to avoid all major pathways of rejection

Franchise of iNK and iT cell therapies addresses all patient subtypes, provides optionality



## Glioblastoma

- **CNTY-103:** Multi-specific (CD133+ EGFR) CAR iNK for recurrent GBM
- **Follow-on candidate**

Multi-tumor antigen targeting addresses heterogeneity in GBM tumor cells

iNK product with local administration may minimize toxicity



## Solid tumors

**Future candidate** to be announced 2022


Leverage  $\gamma\delta$  iT platform to target challenging solid tumors

Pre-clinical data shows dose dependent activity, low risk of CRS and GvHD

# CNTY-101: NEXT GENERATION CD19 TARGETED PRODUCT

## HIGHLY DIFFERENTIATED PROFILE

### Allo-Evasion™ edits




### CNTY-101


First cell product candidate with 6 gene edits introduced with CRISPR-HDR

## ELIPSE-1: PHASE 1 STUDY

- Study to enroll first patient by YE
- Designed to maximize learnings
- Potential to dose as needed with single LD cycle
- Effect of Allo-Evasion on iNK persistence after multiple doses



Current Paradigm




Century Paradigm



# CNTY-103: CENTURY'S FIRST SOLID TUMOR CANDIDATE

## Allo-Evasion™ edits



## UNIQUELY POSITIONED TO ADDRESS CHALLENGES OF GBM


- Acquisition of Empirica provided access to:
  - Validated targets, CARs, preclinical models for GBM
- Initiate IND enabling activities by YE

Challenge	Century's Solution
Trafficking	Local delivery with Ommaya reservoir
Heterogeneity	Targeting EGFR / EGFRvIII and CD133 (cancer stem cell marker)
Toxicity	Minimize risks like CRS with iNK
Persistence	Potential to dose as needed

- Plan to dose without lymphodepletion given Allo-Evasion and local delivery

# PLATFORM ENABLES RAPID PRODUCT EVOLUTION

Proposed Feature	CNTY-101 iNK 1.0	CNTY-103 iNK 2.0	iNK 3.0 Candidate
Cytokine support	Soluble IL-15	mbIL-15	mbIL-15
Innate Activity	+	++ (NKG2A KO)	++ (NKG2A KO)
Undisclosed			✓
PET tracer			✓
<b>Allo-Evasion</b>			
HLA-I KO	✓	✓	✓
HLA-II KO	✓	✓	✓
HLA-E KI	✓	✓	✓
Undisclosed			✓



The background is a dark blue field filled with a complex, web-like network of fine, light blue lines that resemble a neural or cellular network. In the center, there is a large, spherical, textured mass. The left side of this mass is colored in shades of red and orange, while the right side is primarily blue with some orange and yellow highlights. The overall appearance is that of a microscopic or molecular model.

# THANK YOU

---